Phage Therapy Market Study Analysis with Forecast to 2031

"Phage Therapy Market" is poised to grow at a CAGR of 18.29% from 2024 to 2031 according to a new report by InsightAce Analytic.

Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/1094

Latest Drivers Restraint and Opportunities Market Snapshot:
Key factors influencing the global phage therapy market are:
• Shift toward personalized healthcare
• Rising number of patients
• Rising incidence of infectious diseases

The following are the primary obstacles to the phage therapy market's expansion:
• Absence of comprehensive clinical information
• Lack of clarity about the policies
• Increasing worry about microorganisms that are resistant to antibiotics

Future expansion opportunities for the global phage therapy market include:
• Increased investment funding by major market participants
• Growing innovative pharmaceuticals
• Accelerating research and development efforts

Market Analysis:
Multiple bacterial infections, such as those caused by Escherichia coli, Pseudomonas, and Staphylococcus species, have been successfully treated with phage therapy. This has led to impressive progress in phage therapy in various other therapeutic contexts. In addition, ant biotherapy for humans and environmental cleansing are only two potential uses for phages. Additionally, they demonstrated that phase therapy might be utilized as a new antimicrobial agent to fight against antibiotic resistance and several modern phage treatment methods. Furthermore, the necessity for phase therapy would increase in response to this surge in bacterial infections.

List of Prominent Players in the Phage Therapy Market:
• Armata Pharmaceuticals, Inc.
• Adaptive Phage Therapeutics
• AmpliPhi Biosciences
• BiomX (MBcure Ltd.)
• C3J Therapeutics
• Enbiotix
• Eligo Bioscience
• Intralytix, Inc.
• InnoPhage
• iNtODEWorld
• Locus Biosciences
• MicroPhage, Inc.
• Phage International
• PhagoMed Biopharma GmbH
• Pherecydes Pharma SA
• TechnoPhage
• Phagelux
• SNIPR BIOME
• Microgen Russia

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1094

Recent Developments:
• In January 2024, Adaptive Phage Therapeutics, Inc., a biotechnology company in the clinical stage, announced that the first patient had been dosed in the PHAGE clinical study. This study evaluates the efficacy of bacteriophage therapy in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.
• In March 2024, BiomX Inc. and Adaptive Phage Therapeutics, Inc. announced they had entered into a definitive merger agreement. BiomX is a clinical-stage company that studies and develops natural and engineered phage therapies that target specific pathogenic bacteria.
• In January 2024, Technophage, a biopharmaceutical business that focuses on developing and producing biologics, namely those derived from bacteriophages, officially announced the successful dosing of the first patient in this critical stage. This clinical trial (ID: NCT05948592) is to determine if TP-102 is effective in treating diabetic foot ulcers caused by Staphylococcus aureus, Pseudomonas, and Acinetobacter baumannii.

Phage Therapy Market Dynamics:
Market Drivers: Rising Incidence of Infectious Diseases
The increasing prevalence of infectious diseases worldwide is a major component impacting the interest and advancement in phage therapy. Using bacteriophage viruses with the ability to infect and destroy bacteria to treat bacterial infections is known as phage therapy. Because antibiotic-resistant bacteria have increased due to overuse and abuse, so traditional antibiotics are becoming increasingly ineffective against certain ailments. Research investigations and clinical trials investigating the use of phage therapy to treat different bacterial infections are also increasing in number, which is driving the market growth.

Challenges: Lack of Clarity Regarding the Policies and Procedures
There is less certainty regarding the regulatory mechanism for phage therapy than antibiotics. Companies and researchers can find it challenging to bring phage therapies to market due to the absence of a clear regulatory framework, which might create obstacles to the approval and standardization of phage treatments. Additionally, only some people are familiar with phage therapy, and some might be reluctant to accept the concept of utilizing viruses to cure bacterial diseases, hindering the growth of the phage therapy market.

North America is Expected to Grow with the Highest CAGR During the Forecast Period
The North American phage therapy market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. This area is at the forefront of its field because of its well-developed healthcare system, abundant R&D, and regulatory backing for phage therapy. They increased their investment funds, enhanced their comprehension of phage biology, and enhanced the practicability of creating medicines based on phages. This is anticipated to fuel market expansion throughout the forecast period in the area's marketplace.

Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1094

Segmentation of Phage Therapy Market-
By Therapeutic Area-
• Infectious Diseases
• Oncological Disorders
• Other Disorders
By Route of Administration-
• Oral
• Topical
• Rectal
• Intravenous
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Get more information: @ https://www.insightaceanalytic.com/customisation/1094

Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.